170.88
price down icon0.39%   -0.67
after-market アフターアワーズ: 172.00 1.12 +0.66%
loading
前日終値:
$171.55
開ける:
$169.77
24時間の取引高:
929.62K
Relative Volume:
0.77
時価総額:
$17.18B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
26.27
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
-3.52%
1か月 パフォーマンス:
+7.47%
6か月 パフォーマンス:
+29.07%
1年 パフォーマンス:
+27.42%
1日の値動き範囲:
Value
$169.26
$172.57
1週間の範囲:
Value
$169.01
$177.33
52週間の値動き範囲:
Value
$122.14
$181.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1092)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2026-07-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX icon
NBIX
Neurocrine Biosciences Inc
170.88 17.25B 3.10B 668.60M 831.30M 6.5044
TAK icon
TAK
Takeda Pharmaceutical Co Adr
17.15 53.43B 29.91B 1.30B 3.49B 0.4056
HLN icon
HLN
Haleon Plc Adr
10.10 44.52B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
32.03 37.52B 17.53B 1.58B 444.18M 1.3457
ZTS icon
ZTS
Zoetis Inc
76.56 32.24B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
535.67 22.46B 3.17B 1.29B 1.01B 27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Jul 19, 2026

Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price - simplywall.st

Jul 19, 2026
pulisher
Jul 18, 2026

Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside? - simplywall.st

Jul 18, 2026
pulisher
Jul 18, 2026

NEUROCRINE BIOSCIENCES, INC. : WELLS FARGO RAISES TARGET PRICE TO $200 FROM $175 - Bitget

Jul 18, 2026
pulisher
Jul 18, 2026

Price to sales forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView

Jul 18, 2026
pulisher
Jul 17, 2026

NBIX Maintained by Wells Fargo -- Price Target Raised to $200 - GuruFocus

Jul 17, 2026
pulisher
Jul 17, 2026

Wells Fargo Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $200 - Moomoo

Jul 17, 2026
pulisher
Jul 17, 2026

Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences (NBIX) Investors? - simplywall.st

Jul 17, 2026
pulisher
Jul 16, 2026

Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - The Globe and Mail

Jul 16, 2026
pulisher
Jul 16, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening - ChartMill

Jul 16, 2026
pulisher
Jul 16, 2026

BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199 - Moomoo

Jul 16, 2026
pulisher
Jul 15, 2026

Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 15, 2026
pulisher
Jul 14, 2026

Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? - Yahoo Finance

Jul 14, 2026
pulisher
Jul 14, 2026

Neurocrine Price Target Raised to $200.00/Share From $155.00 by Truist Securities - Moomoo

Jul 14, 2026
pulisher
Jul 14, 2026

NBIX Maintained by BMO Capital -- Price Target Raised to $170 - GuruFocus

Jul 14, 2026
pulisher
Jul 13, 2026

Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria

Jul 13, 2026
pulisher
Jul 13, 2026

Neurocrine Biosciences chief legal officer sells $1.79m in stock - Investing.com UK

Jul 13, 2026
pulisher
Jul 13, 2026

Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com - Investing.com South Africa

Jul 13, 2026
pulisher
Jul 13, 2026

[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan

Jul 13, 2026
pulisher
Jul 13, 2026

Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares - Stock Titan

Jul 13, 2026
pulisher
Jul 13, 2026

Truist Financial Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $200 - Moomoo

Jul 13, 2026
pulisher
Jul 13, 2026

Truist raises Neurocrine Bio stock price target on pipeline potential - Investing.com

Jul 13, 2026
pulisher
Jul 13, 2026

Truist raises Neurocrine Bio stock price target on pipeline potential By Investing.com - Investing.com Nigeria

Jul 13, 2026
pulisher
Jul 13, 2026

Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating - Moomoo

Jul 13, 2026
pulisher
Jul 12, 2026

Reasons why investors should consider betting on Neurocrine stock - MSN

Jul 12, 2026
pulisher
Jul 11, 2026

Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left? - simplywall.st

Jul 11, 2026
pulisher
Jul 11, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen - ChartMill

Jul 11, 2026
pulisher
Jul 10, 2026

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill

Jul 10, 2026
pulisher
Jul 10, 2026

Form 144 NEUROCRINE BIOSCIENCES For: 10 July By Investing.com - Investing.com South Africa

Jul 10, 2026
pulisher
Jul 10, 2026

Form 144 NEUROCRINE BIOSCIENCES For: 10 July - Investing.com India

Jul 10, 2026
pulisher
Jul 10, 2026

[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan

Jul 10, 2026
pulisher
Jul 10, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance

Jul 10, 2026
pulisher
Jul 10, 2026

Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline - Yahoo Finance

Jul 10, 2026
pulisher
Jul 10, 2026

Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy? - simplywall.st

Jul 10, 2026
pulisher
Jul 10, 2026

Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing - Moomoo

Jul 10, 2026
pulisher
Jul 09, 2026

Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com - Investing.com India

Jul 09, 2026
pulisher
Jul 09, 2026

Neurocrine Biosciences chief regulatory officer sells $2.6m stock - Investing.com

Jul 09, 2026
pulisher
Jul 09, 2026

Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com - Investing.com South Africa

Jul 09, 2026
pulisher
Jul 09, 2026

Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan - Stock Titan

Jul 09, 2026
pulisher
Jul 09, 2026

Form 144 NEUROCRINE BIOSCIENCES For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Neurocrine Biosciences Inc (NBIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Delaet Ingrid
Chief Regulatory Officer
Jul 10 '26
Sale
181.02
4,367
790,514
16,225
Lippoldt Darin
Chief Legal Officer
Jul 09 '26
Option Exercise
81.49
10,000
814,900
64,729
Lippoldt Darin
Chief Legal Officer
Jul 09 '26
Sale
179.60
10,000
1,796,014
54,729
$17.29
price down icon 0.23%
$25.83
price down icon 0.46%
$535.67
price up icon 1.25%
RDY RDY
$12.60
price down icon 0.79%
$52.72
price up icon 1.50%
大文字化:     |  ボリューム (24 時間):